Company expects US FDA decision on Maxigesic tablets and IV over next six months.
Fri, 07 Jan 2022
AFT Pharmaceuticals has greeted the new year with a letter to investors, confirming its operating profit guidance for the year to the end of March and setting out some key expectations for 2022.
The letter, signed by chair David Flacks and managing director Dr Hartley Atkinson and released to
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
